Hedge Funds Are Buying Aegerion Pharmaceuticals, Inc. (AEGR)
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was in 14 hedge funds' portfolio at the end of the fourth quarter of 2012. AEGR has seen an increase in hedge fund sentiment in recent months.
Rigel Pharmaceuticals Inc (RIGL)
Market is closed
News
- First
- << Previous
- 51 - 57
Is Aegerion Pharmaceuticals, Inc. (AEGR) Going to Burn These Hedge Funds?: Impax Laboratories Inc (IPXL), Pacira Pharmaceuticals Inc (PCRX)
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was in 14 hedge funds' portfolio at the end of December. AEGR has experienced an increase in enthusiasm from smart money in recent months.
Rigel Pharmaceuticals, Inc. (RIGL): Why This Stock Is Poised to Bounce Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company Rigel Pharmaceuticals, Inc...
Johnson & Johnson (JNJ), Rigel Pharmaceuticals, Inc. (RIGL): This Week in Biotech
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
3 Horrendous Health-Care Stocks This Week: Rigel Pharmaceuticals, Inc. (RIGL), Achillion Pharmaceuticals, Inc. (ACHN)
The Motley Fool's annual April Fools' Day joke this year focused on the "hugest bubble in history" that is set to explode. For some health-care stocks, though, the bubble popping was no joke.
AstraZeneca plc (ADR) (AZN), Rigel Pharmaceuticals, Inc. (RIGL): Growing Aches and Pains Sink This Stock
What: Shares of Rigel Pharmaceuticals, Inc.
Endocyte, Inc. (NASDAQ:ECYT), Kythera Biopharmaceuticals Inc (NASDAQ:KYTH): Should You Avoid Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)?
To most stock holders, hedge funds are seen as unimportant, old financial vehicles of the past.
- First
- << Previous
- 51 - 57
Billionaire Hedge Funds
